Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016180 | 0.78 | F10 (0.61) | — | |
| Benzene SCHEMBL10799860 | 0.75 | SIGMAR1 (0.62) | DRD4ALDH1A1KMT2ASMN1; SMN2SIGMAR1 | |
| SCHEMBL3306841 | 0.74 | SIGMAR1 (0.68) | DRD4ALDH1A1KMT2ASMN1; SMN2SIGMAR1 | |
| SCHEMBL29712058 | 0.72 | SIGMAR1 (0.65) | DRD4ALDH1A1KMT2ASMN1; SMN2SIGMAR1 | |
| SCHEMBL4848461 | 0.72 | SIGMAR1 (0.65) | DRD4ALDH1A1KMT2ASMN1; SMN2SIGMAR1 | |
| SCHEMBL12226832 | 0.72 | SIGMAR1 (0.61) | DRD4ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL6787343 | 0.69 | KMT2A (0.98) | CCR4DRD4SLC6A12ALDH1A1KMT2A | |
| SCHEMBL7012011 | 0.69 | F10 (0.52) | — | |
| SCHEMBL29778710 | 0.69 | SIGMAR1 (0.58) | DRD4SIGMAR1 | |
| SCHEMBL17301746 | 0.69 | SIGMAR1 (0.60) | DRD4ALDH1A1KMT2AMCHR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | CCR4 2242/4885DRD4 433/4885SLC6A12 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.